Ed Kelly, PhD, Assistant Director of the Pharmaceutical Bioengineering Extension Program at the University of Washington School of Pharmacy, and co-researcher Jonathan Himmelfarb, MD, are leading a study…
The US Food and Drug Administration (FDA) has approved the immunotherapy avelumab in combination with the tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The…
According to the Associated Press’ search of a U.S. government database, six of the eight currently registered clinical trials studying deep brain stimulation (DBS) for addiction treatment are…
